Debating CRISPR/cas9 and mitochondrial donation: Continuity and transition performances at scientific conferences by Stephens, NS & Dimond, B
Engaging Science, Technology, and Society 2 (2016), 312-321    DOI:10.17351/ests2016.080 	
Copyright © 2017 (Neil Stephens and Rebecca Dimond). Licensed under the Creative Commons Attribution Non-
commercial No Derivatives (by-nc-nd).  Available at estsjournal.org. 	
 
Debating CRISPR/cas9 and Mitochondrial Donation: 
Continuity and Transition Performances at Scientific Conferences 
 
 
NEIL STEPHENS1 
BRUNEL UNIVERSITY LONDON 
 
REBECCA DIMOND2 
CARDIFF UNIVERSITY 
 
 
Abstract 
Conferences are important performative sites. Here we detail a UK science policy conference 
debating the novel biomedical techniques CRISPR/cas9 and mitochondrial donation. Both 
techniques have received significant attention from scientists and bioethicists about their clinical 
potential, social implications, and the prospects of genetic and germline modification. In many 
countries the policy debates on regulating both technologies is ongoing and operating in tandem. 
The UK, however, is operating in a distinct policy context in that mitochondrial donation was 
formally legalized under license in 2015, meaning the British CRISPR/cas9 debates occur in the 
light of a confirmed policy position on mitochondrial donation. Our analysis of the Progress 
Educational Trust 2015 annual conference ‘From Three-Person IVF to Genome Editing’ argues 
that this event conducted important staging work in articulating the relationship between these 
two technologies in the UK. These efforts constitute what we call a ‘transition performance’ that 
(i) enacted the successful resolution of the mitochondrial donation policy debate, (ii) performed 
the success of British biomedical politics, and (iii) opened the space for a public debate on 
CRISPR/cas9 in line with a specifically configured set of legitimacy practices. Subsequently the 
conference contrasts to many other conferences that fit what we term a ‘continuity performance’ 
that seek to assert consistency and progress through iteration. We close by articulating further 
applications and developments of these notions in Science and Technology Studies. 
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Introduction  
The last two years have witnessed intense debates about the future potential and risks of 
controversial and novel technologies that could enable human genetic modification. Here we use 
the example of a conference about two such technologies––CRISPR/cas9 and mitochondrial 
donation––to articulate how conferences can be sites of transition performance that enact specific 
forms of biomedical political culture. 
 
 
Studying Conferences in STS  
Conferences are integral to scientific practice but remain under-analyzed within Science and 
Technology Studies (STS) (González-Santos and Dimond 2015). This is an oversight, as 
conferences are places of work akin to the laboratory or clinic: they enable members of a 
community to meet, to collaborate, and to discuss and present their work. Conferences are also 
symbolic of the ties that bind a community; they offer the opportunity for achievements to be 
celebrated, reputations to be established, and can simultaneously reflect, and shape, the nature of 
a field. Collins (2004) argues that conferences are sites in which “the community learns the 
etiquette of today’s truth” (p 451). For Wainwright and Williams (2008) they are significant places 
of performance. We expand this emphasis by introducing two categories of conference 
performativities: “continuity performances” and “transition performances.” 
 
 
Conference Performativities 
The STS notion of performativity is prefigured in many classics of philosophy and sociology 
(Butler 1993; Dewey 1946; Garfinkel 1967; Goffman 1959; Lyotard 1984; Peirce 1905; see Muniesa 
2014 for a detailed account), and has found expression in works including Pickering (1995), 
Callon (1998), Brown and Michael (2003), and MacKenzie (2006). All focus on the capacity of 
discourses and actions to bring into being the identities, practices, and knowledge claims they 
operate to describe. Speaking of social science, Law and Urry suggest scientific “inquiry and its 
methods are productive: they (help to) make social realities and social worlds. They do not simply 
describe the world as it is, but also enact it” (Law and Urry 2004: 390-1, emphasis in original).  
 Conferences also enact. They make and remake worlds. Most scientific conferences are 
“continuity performances”: a field, a research focus, or a set of methods is enacted as coherent 
and consistent. Importantly, this does not mean stasis: the community moves forward through 
articulating findings and innovations. Progress becomes a mechanism that allows change while 
retaining continuity with the past. 
We contrast “continuity performances” with an example of “transition performance,” in 
which a conference enacts progress through distinction, through rendering the modes of 
accountability to the recent past as different from those of the near future. We do so by focusing 
upon a UK science policy conference hosted by the Progress Educational Trust (PET) about two 
controversial biomedical technologies: CRISPR/cas9 and mitochondrial donation. We 
demonstrate how the PET conference worked, firstly, to enact the transition of mitochondrial 
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donation from a status of open debate to one of successful closure, and, secondly, to introduce 
CRISPR/cas9 as a new debate in British biomedical political culture. In doing so, it staged a 
transition performance that rendered mitochondrial donation as evidence of that political 
culture’s success. This occurred through excluding dissenting voices from the mitochondrial 
donation case, through asserting the strength of British biomedical political culture, and by 
staging and legitimizing multiple perspectives on CRISPR/cas9. 
 
 
Mitochondrial Donation and CRISPR/cas9 
In February 2015, the UK became the first (and still only) country in the world to legalize 
mitochondrial donation. Mitochondrial donation uses part of a donated egg in an In Vitro 
Fertilization (IVF) cycle to allow women with maternally inherited mitochondrial disease to have 
healthy, genetically related children. The techniques are controversial because genes from the 
mitochondrial donor can be passed on to future generations (known as “germline modification”) 
(Baylis 2013; Bredenoord et al. 2011). The resulting child would have three genetic contributors 
(nuclear genes from the intending mother and father and mitochondrial genes from the egg 
donor) (Dimond 2015). The decision to change the law and allow the techniques followed several 
years of consultations, policy debates, and parliamentary votes, which culminated in a consensus 
that mitochondrial donation did not constitute genetic modification (which had been redefined as 
only involving the modification of nuclear genes) (DoH 2014). While the UK is the first to legalize 
the techniques, there are other countries in which the techniques are neither formally legal nor 
illegal. In 2003 a team in China lead by Prof. John Zhang attempted a similar procedure involving 
mitochondrial transfer in a human IVF procedure. Although three foetuses developed, it did not 
result in any live births (Cohen and Malter 2016; Zhang et al. 2016a). In September 2016 it was 
announced that Prof. Zhang’s new USA based team had again conducted a mitochondrial 
donation IVF technique, this time performing the procedure in Mexico, and this time leading to 
the birth of a seemingly healthy baby boy (Hamzelou 2016; Zhang et al. 2016b). In contrast, the 
UK is yet to see a human pregnancy using a mitochondrial donation technique. 
 CRISPR/cas9 is a new type of gene-editing technique that allows the editing of hundreds 
of genes at once. It could be used to address complex disorders and character traits much more 
cheaply, quickly, and efficiently than any prior technique (Chan et al. 2015). Liang published the 
first work on CRISPR/cas9 gene-editing in abnormal human embryos as recently as 2015 (Liang 
et al. 2015), and although it has a short history, it has swiftly become a hot topic among biologists 
and bioethicists. Already we have calls for a moratorium (Hawkes 2015; Lanphier et al. 2015), a 
US government task force assessing biohacking risk (Knoepfler 2016), a patent dispute (Sheridan 
2014), and a US Gene-editing Summit (Jasanoff et al. 2015). CRISPR/cas9 kits are now available 
online and the UK recently granted the world’s first research license for human embryonic work, 
although this is predated by Liang’s unlicensed work in China (Callaway 2016; Liang et al. 2015). 
Through CRISPR/cas9 the technical capacity to genetically modify the human genome––and pass 
those modifications to future generations––could soon be a realistic possibility (Savulescu et al. 
2015). 
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 In most countries debates about the safety and ethics of mitochondrial donation and 
CRISPR/cas9 are running concurrently. The UK is unique in that CRISPR/cas9 is being discussed 
after mitochondrial donation has been formally legalized. 
 
 
UK Biomedical Political Culture and the Progress Educational Trust 
The UK has developed a distinctive biomedical political culture over the last four decades 
featuring consultation processes, arms-length bodies, and a permissive but highly regulated and 
bureaucratized licensing approach to conducting ethically sensitive biomedical work. It is 
characterized by an emphasis on evidential culture (Salter et al. 2015), institutionalized ethics 
(Reubi 2013), and performances of transparency (Jasanoff 2005; Stephens et al. 2013). This model 
has been mobilized most effectively in a succession of embryo research programs, including IVF 
(Mulkay 1993), human embryonic stem cells (Mikami and Stephens 2016; Salter and Salter 2007), 
and more recently mitochondrial donation, that seek to enact the UK’s global leadership in these 
areas.  
 The December 2015 Progress Educational Trust (PET) annual conference “From three-
person IVF to Genome editing: The Science and Ethics of Engineering the Embryo” is an example 
of transition performance, a site of political action, and an important location for STS-informed 
empirical analysis. PET is a small charitable organization that adopts a distinct but significant 
position within UK genetic and assisted conception policy debates. It performs a dual role as 
(typically pro-scientific) advocacy group and host of open debate. In its advocacy role, it 
submitted supportive responses to consultations on mitochondrial donation to the Human 
Fertilization and Embryology Authority (HFEA), the Nuffield Council on Bioethics, and the 
Department of Health. In its debate hosting role, it runs the web-based weekly newsletter 
“Bionews” and events including topic specific workshops and annual conferences. In previous 
years, the annual conference has focused on embryo research (2011), fertility treatment (2012), 
twins in genetics and fertility treatment (2013), the commercialization of life (2014) and most 
recently, the science and ethics of engineering the embryo. The 2015 event took place in the 
Department of Health conference center in London. This public event was attended by an 
audience of more than 300, including scientists, ethicists, campaigners, journalists, government 
officials, social scientists and, no doubt, patients and interested citizens. 
 
 
From Three-person IVF to Genome Editing: Documenting Transition Performance 
In this section we demonstrate how the PET conference acted to record the technologies (in this 
case, mitochondrial donation and CRISPR/Cas9) as socially significant and worthy of public 
debate. It also worked as a transition performance to denote a shift for mitochondrial donation 
from debate to policy success, while staging the initial UK policy reflections and engagement 
encounter for CRISPR/cas9, and acting as a site of the nuanced positioning of the continuity and 
distinctness of the two technologies. It was also a restatement of a dominant sense of British 
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biomedical political culture that has its roots in the IVF debates of the 1980s and continued 
through human embryonic stem cells, hybrid embryos, and now pre-implantation CRISPR/cas9. 
 
Enacting the successful resolution of the mitochondrial donation policy debate 
The morning featured a session on mitochondrial donation. The three speakers were: the scientist 
most visibly associated with the techniques, Prof. Doug Turnbull (whose talk was entitled “Why 
do we need mitochondrial donation?”); chair of the HFEA, Sally Cheshire (“Why the UK is the 
best place for mitochondrial donation”), and Viscount Matt Ridley (who described his and his 
colleagues’ work to steer the Lord’s debate towards a positive outcome). The presentations 
continued a narrative that featured heavily in the pre-vote debates about the suffering and 
tragedy of patient-families. This given, two notable differences between pre- and post-
parliamentary debate accounts were evident. Firstly, the PET conference accounts framed 
families with mitochondrial mutations as key beneficiaries of the collective policy success 
achieved through legalization, as opposed to their previous framing as potential victims of a vote 
against the techniques. Secondly, family representatives themselves were not present on stage at 
the PET event. This stands in contrast to many pre-vote public debates in which they were key 
speakers. The absence of patient-family voices suggests that on this occasion it was deemed 
unnecessary to deploy individualized and embodied suffering narratives as a tool for persuasion. 
Instead, this role was conferred to professionalized speakers and thus worked to enact their 
status as legitimate representatives of patient-family perspectives. 
 A second set of absent voices were those opposed to legalizing the mitochondrial 
donation techniques. PET have organized several panels discussing mitochondrial donation over 
the last two years, but this was the first that did not feature a speaker against the techniques on 
stage. In doing so, the conference effectively asserted the irrelevance of counter-mitochondrial 
donation perspectives to the British debate. Through this silencing of opposing voices, and 
conferring the capacity to speak on behalf of patient-families to biomedical, regulatory, and 
political professionals, the session was both celebrative and constitutive of the correctness of 
legalizing the techniques. It was the first component of the transition performance, rendering the 
recent past as accountable to the authority of the victors, and closing down debate on the topic. 
 
Performing the success of British biomedical politics 
Sally Cheshire’s morning presentation, “Why the UK is the best place for mitochondrial 
donation,” was followed by another invocation of Britishness in the afternoon, as the Chief 
Scientific Adviser to the UK Government––Prof. Sir Mark Walport––addressed “Why the UK 
should be leading the discussion on embryo engineering.” He produced a classic mainstream 
narrative on the UK's successful biomedical political culture that featured the boundary work of a 
science/value distinction and a restatement of the HFEA’s world-leading capacity for conducting 
excellent public consultation and its highly regulated but permissive licensing systems. This “UK 
as gold standard” trope is both accounted for, and enacted through, conferences of this form. 
They work to stage accountability through engagement and purposefulness through open 
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debate. Importantly, through this move, mitochondrial donation is transitioned from being an 
open topic for discussion to being evidence of the UK system’s success. 
 
Transitioning to CRISPR/cas9 through performing legitimacy practices 
The latter sessions of the conference focused on CRISPR/cas9. The discussion was implicitly 
staged as a milestone in opening UK policy debate on this issue, with the early talks explaining 
what CRISPR/cas9 is and what it could do. Regular features of biomedical political debate were 
quickly evident: metaphors presenting CRISPR/cas9 invoked bridges between genes, and the 
craft skill of the carpenter was likened to the scientist performing gene editing. Robin Lovell-
Badge, scientist and prominent proponent of mitochondrial donation, articulated the potential 
uses of CRISPR/cas9, but argued that while he supports research development in the area, this 
did not equal endorsement for clinical use at this stage in the discussions. 
 The conference closed with a session on the ethics and law of engineering the embryo. 
Panelists Emily Jackson (lawyer), John Harris (bioethicist), Calum MacKellar (bioethicist), and 
Brendan McCarthy (The Church of England) articulated a range of opinions (contrasting starkly 
with the unified voices of the mitochondrial donation session). This given, only MacKellar spoke 
with sustained hostility towards CRISPR/cas9, and was singled out for thanks by the chair for 
representing these views amongst predominantly supportive speakers. This act of thanks is part 
of a nuanced etiquette of political legitimacy that works to show a sincere gratitude for an 
opinion that ultimately goes against the dominant trajectory articulated at the event. It is 
celebrative of the capacity to host diverse views, while knowing that ultimately this counter 
narrative is of a type that was unsuccessful in the previous mitochondrial donation debate, and 
may be so again from CRISPR/cas9. While this session was about CRISPR/cas9, all speakers 
drew upon the mitochondrial case as a resource in their accounts, stressing continuities and 
discontinuities between the two technologies. Key examples of this include speakers contesting 
which metaphors were appropriate to use for each technology, whether the timeframe for 
developing policy was too fast or too slow, and Britain’s status as pioneer or maverick (with the 
latter exemplified in MacKellar’s talk titled “Brave New British Babies,” a reference to Aldous 
Huxley’s (1932) dystopian novel on future IVF technologies). 
 
 
Transition and Continuity Performances and the Making of Biological Debate 
The PET conference enacted transition through staging open debate on CRISPR/cas9 (between 
invited speakers), while also consigning previous debate on mitochondrial donation to the past 
(through celebratory rhetoric and exclusion of contesting voices). It also conferred legitimacy to 
its own practices through a discourse of ongoing British success in this area. This British 
mainstream desire to be the first and the best to regulate mitochondrial donation imprints a pre-
history, a narrative resource, and pre-drawn battle lines on embryo editing discussions. Across 
this history, by hosting multiple opinions on CRISPR/cas9 but only victorious voices on 
mitochondrial donation, the PET event rendered modes of accountability for the recent past as 
different to those of the near future. 
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 More broadly, we can understand the PET conference as one performative moment in a 
succession of enactments around UK biomedical politics. Others include the 2015 parliamentary 
votes that approved mitochondrial donation licensing, and the early 2016 HFEA decision to allow 
CRISPR/Cas9 in healthy human embryos, which again made the UK the first country to give 
regulatory approval for a controversial technology (Callaway 2016). These policy decisions fit 
more closely with classical notions of performativity in that they legally establish that which they 
state, and remake legal worlds (Austin 1962). This noted, the PET conference remains a 
significant site of the performance of the political process that supports these decisions, and 
requires STS attention. 
 
 
Analyzing Conference Performativities in Other Contexts 
The analysis here can be profitably extended by exploring other empirical contexts, documenting 
other modes of performativity, and further detailing their accomplishment. Conferences draw 
people together and (re)configure the aims and boundaries of their fields. They are constitutive of 
a field, not just reflective of it. Being attentive to how conferences perform this practical and 
symbolic work could be central to STS inquiry, highlighting ways in which different types of 
conference on different topics may enact different worlds in different ways. A patient or user 
conference can stage the collective effervescence of shared activism (Dimond et al. 2015); a 
scientific conference can make and remake disciplines; and a science policy conference like PET 
can enact the discourses of legitimacy of a national biomedical political culture. Analysts can ask 
what is performed, what is not, and how these performances are staged. In many conferences 
these are continuity performances that enact progress through stability. Identifying the 
mechanisms by which this occurs in different contexts is a rich area for STS exploration. Another 
area of expansion is adding further to the typology of continuity and transition performances 
through the empirical documentation of other types of conference enactment. By pursuing this 
important work the STS scholar is offering the richness and depth to conference studies that 
already furnishes laboratory and clinic ethnographies. In doing so, they further enrich STS. 
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